Recent

% | $
Quotes you view appear here for quick access.

Sequenom Inc. Message Board

  • slobbermut slobbermut Jul 2, 2010 10:53 AM Flag

    Wedbush Comments

     

    Wedbush notes, based on conversations with lab players already using next generation sequencing technology in clinical operations, it believes that the all in costs per sample (assuming 4-plex) could be $500-$600 at present and could come down significantly with new technologies. As a reminder, SQNM could face competition from companies taking the cell-free nucleic acid approach as well as the intact fetal cell approach. Firm currently views fetal cell-based companies as the most threatening to SQNM's Down Syndrome strategy and progress in this area has recently accelerated.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SQNM
2.95-0.04(-1.50%)Jul 2 4:00 PMEDT